To investigate this hypothesis, we tested the effects of PAQR8 overexpression or PAQR8 deletion on the response to treatment with doxorubicin or docetaxel, chemotherapeutic agents commonly used in treating breast cancer patients. This evidence concerns the gene PAQR8 and breast carcinoma.